Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Xuantai Pharmaceuticals: The collaborative product Enzalutamide tablets approved by the National Medical Products Administration for market launch
Xuantai Pharmaceutical Announcement: Recently, the Enzalutamide tablets developed in collaboration with the company received the “Drug Registration Certificate” issued by the National Medical Products Administration, approving the launch of Enzalutamide tablets. Enzalutamide is an androgen receptor inhibitor, suitable for the treatment of “metastatic hormone-sensitive prostate cancer (mHSPC) in adult patients; non-metastatic castration-resistant prostate cancer (NM-CRPC) with high risk of metastasis in adult patients; and metastatic castration-resistant prostate cancer (CRPC) in adult patients who have failed androgen deprivation therapy (ADT), are asymptomatic or have mild symptoms, and have not received chemotherapy.”